Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010)

Br J Dermatol. 2015 Jul;173(1):247-9. doi: 10.1111/bjd.13623. Epub 2015 May 26.

Authors

E Levy-Nissenbaum¹, H B Thio², P Burstein³, D Thaci⁴

Affiliations

¹ BioLineRx Ltd, Jerusalem, Israel.
² Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.
³ Innovative Pharmaceutical Concepts Inc., Ramat HaSharon, Israel.
⁴ Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Lübeck, Lübeck, Germany.

PMID: 25524163
DOI: 10.1111/bjd.13623

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Cutaneous
Adolescent
Adult
Aged
Aged, 80 and over
Caustics / administration & dosage*
Drug Combinations
Formates / administration & dosage*
Humans
Keratolytic Agents / administration & dosage*
Keratosis, Seborrheic / drug therapy*
Middle Aged
Treatment Outcome
Trichloroacetic Acid / administration & dosage*
Young Adult

Substances

BL-5010
Caustics
Drug Combinations
Formates
Keratolytic Agents
formic acid
Trichloroacetic Acid